Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cardiff Oncology, Inc.

Get SEC filing alerts via email and in your feed for Cardiff Oncology, Inc.

CRDF

Cardiff Oncology, Inc.

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc. is a biotechnology company focused on developing targeted cancer therapies, primarily through PLK1 inhibition. Its lead candidate, onvansertib, is an oral, highly selective PLK1 inhibitor used in combination with standard chemotherapies for various cancers, including metastatic colorectal, pancreatic, lung, and breast cancers. The company leverages biomarker-driven clinical trials and strategic partnerships to address unmet medical needs in oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cardiff Oncology, Inc.

1
1
Cardiff Oncology, Inc. Cardiff Oncology Reports $12.4 Million Net Loss in Q1 2026, Appoints New Leadership

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Cardiff Oncology, Inc. Cardiff Oncology Reports $45.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cardiff Oncology, Inc. Cardiff Oncology Reports Q3 2025 Financial Results with $11.3M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cardiff Oncology, Inc. Cardiff Oncology Reports Q2 2025 Financial Results with Increased Net Loss and Decreased Revenues

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cardiff Oncology, Inc. Cardiff Oncology Reports $13.4 Million Net Loss in Q1 2025, Revenue Declines

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cardiff Oncology, Inc. Cardiff Oncology Reports $0.7 Million Revenue and $45.5 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Cardiff Oncology, Inc. Cardiff Oncology Reports Decline in Assets, Increase in Liabilities, and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments